Sacred Leaves Private Limited

Sacred Leaves Private Limited is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on December 3, 2019, in New Delhi, the company operates under the Corporate Identification Number (CIN) U51909DL2019PTC358299. The authorized share capital is ₹5 million, with a paid-up capital of ₹4.1 million. The registered office is located at Property No. 74, Ground Floor, Gali No. 1, Govindpuri, Kalkaji, New Delhi, Delhi 110019. The company is privately held and unlisted. As of the latest available data, Sacred Leaves Private Limited employs between 11 to 30 people.

Sacred Leaves Private Limited operates manufacturing facilities in New Delhi, India. While specific details regarding plant capacities and specializations are not publicly disclosed, the company's focus on finished pharmaceutical formulations suggests that these facilities are equipped to produce a range of dosage forms, including tablets, capsules, syrups, and injections. The facilities are likely designed to adhere to Good Manufacturing Practices (GMP) to ensure product quality and compliance with international standards.

The leadership team of Sacred Leaves Private Limited comprises:

• Aqueel Ahmad: Director since July 4, 2025.

• Sami Ahmad: Director since October 1, 2020.

• Shakeel Ahmad: Director since December 3, 2019.

The company's financial performance has shown significant growth, with a 95.84% increase in total revenue for the financial year ending March 31, 2023.

Sacred Leaves Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including herbal products and antiviral medications. The company's total export value is $564,000 USD, with 4,879 shipments across 4 products in 2 therapeutic categories. The top five products exported are:

• Herbal Products: $457,000 USD, ranking #9 with a 2.4% market share.

• Velpatasvir: $77,000 USD, ranking #10 with a 0.3% market share.

• Ledipasvir: $27,000 USD, ranking #4 with a 2.4% market share.

• Gutika: $3,000 USD, ranking #10 with a 2.2% market share.

The primary therapeutic categories are Ayurvedic & Herbal Products (81.6%) and Antiviral & HIV Medications (18.4%). The company's portfolio is highly concentrated, with the top five products accounting for 100% of the export value.

Sacred Leaves Private Limited has demonstrated a growing presence in emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's focus on herbal and antiviral products aligns with the increasing demand for affordable and effective healthcare solutions in these regions. While specific details regarding WHO prequalification are not publicly available, the company's export activities suggest a commitment to meeting international quality standards, which is essential for accessing these markets.

The company's export strategy appears to be concentrated on a select range of products, primarily herbal and antiviral formulations. This focus may indicate a strategic decision to leverage expertise in these areas. However, the high concentration of export value in the top five products suggests potential risks associated with market fluctuations and regulatory changes. Diversifying the product portfolio and exploring new therapeutic areas could mitigate these risks and support sustainable growth.

Specific details regarding Sacred Leaves Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's export focus on herbal and antiviral products suggests that it may be targeting markets with less stringent regulatory requirements. To enhance its presence in regulated markets like the United States, obtaining FDA approvals and certifications would be advantageous.

While specific information regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certifications for Sacred Leaves Private Limited is not publicly disclosed, the company's export activities to various international markets imply adherence to recognized quality standards. Achieving WHO prequalification and EU GMP certification would further validate the company's commitment to quality and facilitate access to additional markets.

Sacred Leaves Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facilities are likely licensed by the CDSCO, ensuring compliance with national standards for pharmaceutical products. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available. Maintaining compliance with CDSCO regulations is essential for the company's operations and export activities.

As of the latest available information, there are no publicly disclosed records of Form 483 observations, warning letters, or import alerts associated with Sacred Leaves Private Limited. This suggests a clean regulatory record, which is favorable for the company's reputation and operations.

In the Ayurvedic and herbal product segment, Sacred Leaves Private Limited faces competition from established Indian pharmaceutical companies with a global presence. In the antiviral and HIV medication category, the company competes with both multinational corporations and other Indian manufacturers. While specific market share data is not available, the company's export value of $564,000 USD indicates a modest presence in these competitive markets. To enhance its competitive position, the company could consider expanding its product portfolio and strengthening its brand presence.

Sacred Leaves Private Limited's focus on herbal and antiviral products positions it to meet the growing demand for natural and effective healthcare solutions. The company's commitment to quality, as evidenced by its export activities, serves as a competitive advantage. However, the high concentration of export value in a few products suggests that diversifying the product portfolio could further strengthen its market position.

Currently, Sacred Leaves Private Limited's strategic direction appears to be focused on exporting herbal and antiviral pharmaceutical formulations. The company's concentration on a limited product range may present challenges in terms of market diversification and risk management. Expanding into generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services could provide new growth avenues. A strategic review to identify and pursue these opportunities would be beneficial for the company's long-term success.

Sacred Leaves Private Limited has demonstrated a consistent track record in exporting pharmaceutical formulations, with a total export value of $564,000 USD and 4,879 shipments. The company's focus on herbal and antiviral products indicates a specialization in these therapeutic areas. While specific reliability indicators are not publicly available, the company's active export activities suggest a commitment to meeting international standards and customer expectations.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's facility registration with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Verify compliance with World Health Organization Good Manufacturing Practices.

• EU GMP Certification: Ensure adherence to European Union Good Manufacturing Practices.

• ISO Certification: Check for International Organization for Standardization certifications relevant to pharmaceutical manufacturing.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the company.

Importers should undertake the following steps to ensure a thorough evaluation of Sacred Leaves Private Limited:

• Verify Regulatory Compliance: Confirm the company's adherence to relevant regulatory standards, including FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Financial Stability: Review the company's financial statements to evaluate its financial health and stability.

• Evaluate Product Quality: Request samples and conduct quality assessments to ensure product standards meet expectations.

• Check References: Obtain feedback from other clients or partners